Therapeutic effect of ARBs on insulin resistance and liver injury in ptients with NAFLD and chronic hepatitis C: A pilot study

International Journal of Molecular Medicine

Volumn 22, Issue 4, 2008, Pages 521-527

  Enjoji, Munechika ^a,b   Kotoh, Kazuhiro ^a   Kato, Masaki ^a   Higuchi, Nobito ^a   Kohjima, Motoyuki ^a   Nakashima, Manabu ^b   Nakamuta, Makoto ^c  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

Angiotensin II receptor blocker; Chronic hepatitis C; Insulin resistance; Non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIVER PROTECTIVE AGENT; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; HEPATITIS C; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER DISEASE; LIVER INJURY; LIVER PROTECTION; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PILOT STUDY; PRIORITY JOURNAL; THERAPY EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; BENZIMIDAZOLES; BENZOATES; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HOMEOSTASIS; HUMANS; HYPERTENSION; IMIDAZOLES; INCIDENCE; INSULIN RESISTANCE; JAPAN; MALE; MIDDLE AGED; PILOT PROJECTS; TETRAZOLES;

EID: 54049086556     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm_00000051     Document Type: Article

References (48)

1. Farrell GC and Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43: S99-S112, 2006.
2. Angulo P: GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 25: 883-889, 2007.
3. Mule G and Cerasola G: The metabolic syndrome as a prohypertensive state. Am J Hypertens 21: 17-22, 2008.
4. Kashyap SR and Defronzo RA: The insulin resistance syndrome: physiological considerations. Diab Vasc Dis Res 4: 13-19, 2007.
5. Rader DJ: Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes. Am J Med 120: S12-S18, 2007.
6. Ferder L, Inserra F and Martinez-Maldonado M: Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress. Curr Hypertens Rep 8: 191-198, 2006.
7. Morisco C, Lembo G and Trimarco B: Insulin resistance and cardiovascular risk: new insights from molecular and cellular biology. Trends Cardiovasc Med 16: 183-188, 2006.
8. Schmieder RE: Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 18: 720-730, 2005.
9. Ruilope LM, Rosei EA, Bakris GL, Mancia G, Poulter NR, Taddei S, et al: Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press 14: 196-209, 2005.
10. Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, et al: Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Semin Nephrol 24: 147-157, 2004.
11. Dahlof B: Prevention of stroke in patients with hypertension. Am J Cardiol 100: 17-24, 2007.
12. Kutz TW and Pravenec M: Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the rennin-angiotensin system. J Hypertens 22: 2253-2261, 2004.
13. Fogari R and Zoppi A. Antihypertensive drugs and fibrinolytic function. Am J Hypertens 19: 1293-1299, 2006.
14. Israili ZH, Lyoussi B, Hernandez-Hernandez R and Velasco M: Metabolic syndrome: treatment of hypertensive patients. Am J Ther 14: 386-402, 2007.
15. Folli F, Kahn CR, Hansen H, Bouchie JL and Feener EP: Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels - a potential role for serine phosphorylation in insulin/ angiotensin II crosstalk. J Clin Invest 100: 2158-2169, 1997.
16. Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, et al: Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43: 1003-1010, 2004.
17. Janke J, Engeli S, Gorzelniak K, Luft FC and Sharma AM: Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51: 1699-1707, 2002.
18. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Eng J Med 355: 2297-2307, 2006.
19. Lutchman G, Promrat K, Kleiner DE, Heller T, Ghany MG, Yanovski JA, et al: Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 4: 1048-1052, 2006.
20. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, et al: Blockade of the rennin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 22: 1977-1982, 2004.
21. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T and Kutz TW: Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47: 1003-1009, 2006.
22. Miura Y, Yamamoto N, Tsunekawa S, Tagichi S, Eguchi Y, Ozaki N and Oiso Y: Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 28: 757-758, 2005.
23. Vitale C, Mercuro G, Castglioni C, Cornoldi A, Tulli A, Fini M, et al: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 4: 6, 2005.
24. Mendez-Sanchez N, Arrese M, Zamora-Valdes D and Uribe M: Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 27: 423-433, 2007.
25. Sanyal AJ: Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2: 46-53, 2005.
26. Miele L, Forgione A, Hernandez AP, Gabrieli ML, Vero V, DiRocco P, et al: The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis. Eur Rev Med Pharmacol Sci 9: 273-277, 2005.
27. Marchesini G, Marzocchi R, Agostini F and Bugianesi E: Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 16: 421-427, 2005.
28. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, et al: Molecular characterization of new selective peroxisome proliferators-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 54: 3442-3452, 2005.
29. Kurtz TW: New treatment strategies for patients with hypertension and insulin resistance. Am J Med 119: S24-S30, 2006.
30. Pershadsingh HA: Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferators-activated receptor γ. Int J Biochem Cell Biol 38: 766-781, 2006.
31. Clasen R, Schupp M, Foryst-Ludwig A. Sprang C, Clemenz M, Krikov M, et al: PPARγ-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46: 137-143, 2005.
32. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, et al: of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 70: 1717-1724, 2006.
33. Koike K and Miyoshi H: Oxidative stress and hepatitis C viral infection. Hepatol Res 34: 65-73, 2006.
34. Koike K and Moriya K: Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. J Gastroenterol 40: 329-336, 2005.
35. Mitsuyoshi H, Itoh Y, Sumida Y, Minami M, Yasui K, Nakashima T and Okanoue T: Evidence of oxidative stress as a cofactor in the development of insulin resistance in patients with chronic hepatitis C. Hepatol Res 38: 348-353, 2008.
36. Vidali M, Tripodi MF, Ivaldi A, Zampino R, Occhino G, Restivo L, et al: Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol 48: 399-406, 2008.
37. Yoneda M, Saito S, Ikeda T, Fujita K, Mawatari H, Kirikoshi H, et al: Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepat 14: 600-607, 2007.
38. Pazienza V, Clement S, Pugnale P, Conzelman S, Foti M, Mangia A and Negro F: The hepatitis C virus core protein of genotype 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 45: 1164-1171, 2007.
39. Baneriee S, Saito K, Ait-Goughoulte M, Meyer K, Ray RB and Ray R: Hepatitis C virus core protein upregulates serine phosphorylation of IRS-1 and impairs downstream Akt/Pkb signaling pathway for insulin resistance. J Virol 82: 2606-2612, 2007.
40. Furusyo N. Sawayama Y, Maeda S, Toyoda K, Takeoka H, Murata M, et al: High molecular weight form of adiponectin levels of Japanese patients with chronic hepatitis C virus infection. Hepatol Res 37: 1052-1061, 2007.
41. Cua IHY, Hui JM, Bandara P, Kench JG, Farrell GC, McCaughan GW and George J: Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 46: 66-73, 2007.
42. Yano Y, Hoshide S, Ishikawa J, Noguchi C, Tukui D, Takanori H, et al: The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. Am J Hypertens 20: 565-572, 2007.
43. Fliser D, Buchholz K and Haller H: Anitiinflammation effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110: 1103-1107, 2004.
44. Fujimito M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, et al: An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 576: 492-497, 2004.
45. Piccoli C, Scrima R, D'Aprile A, Ripoli M, Lecce L, Boffoli D and Capitanio N: Mitochondrial dysfunction in hepatitis C virus infection, Biochim Biophys Acta 1757: 1429-1437, 2006.
46. Wei Y, Rector RS, Thyfault JP and Ibdah JA: Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 14: 193-199, 2008.
47. Wei Y, Chen K, Whaley-Connell AT, Stump CS, Ibdah JA and Sowers JR: Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Phgiol 294: R673-R680, 2008.
48. Yamaguchi K, Ura N, Murakami H, Togashi N, Hyakukoku M, Higashiura K and Shimamoto K: Olmesartan ameliorates insulin sensitivity by modulating tumor necrosis factor-α and cyclic AMP in skeletal muscle. Hypertens Res 28: 773-778, 2005.